Jeff Yass’s Theriva Biologics TOVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.02K | Buy |
+24,064
| New | +$7.13K | ﹤0.01% | 13177 |
|
|
2024
Q1 | – | Sell |
-428
| Closed | -$4.61K | – | 13334 |
|
|
2023
Q4 | $4.61K | Buy |
+428
| New | +$5.27K | ﹤0.01% | 12131 |
|
|
2023
Q2 | – | Sell |
-427
| Closed | -$7.46K | – | 13146 |
|
|
2023
Q1 | $7.46K | Buy |
+427
| New | +$8.86K | ﹤0.01% | 12252 |
|
|
2022
Q4 | – | Sell |
-656
| Closed | -$16K | – | 13681 |
|
|
2022
Q3 | $16K | Buy |
656
+499
| +318% | +$19.2K | ﹤0.01% | 12680 |
|
|
2022
Q2 | $8K | Buy |
157
+82
| +109% | +$4.69K | ﹤0.01% | 12553 |
|
|
2022
Q1 | $5K | Buy |
+75
| New | +$5.11K | ﹤0.01% | 12818 |
|
|
2021
Q4 | – | Sell |
-88
| Closed | -$10K | – | 13914 |
|
|
2021
Q3 | $10K | Buy |
+88
| New | +$10.9K | ﹤0.01% | 12605 |
|
|
2021
Q1 | – | Sell |
-63
| Closed | -$6K | – | 12861 |
|
|
2020
Q4 | $6K | Buy |
+63
| New | +$5.52K | ﹤0.01% | 10929 |
|
|
2020
Q2 | – | Sell |
-984
| Closed | -$79K | – | 10935 |
|
|
2020
Q1 | $79K | Buy |
+984
| New | +$112K | ﹤0.01% | 9459 |
|
|
2019
Q4 | – | Sell |
-100
| Closed | -$11K | – | 10649 |
|
|
2019
Q3 | $11K | Buy |
100
+60
| +150% | +$7.25K | ﹤0.01% | 10012 |
|
|
2019
Q2 | $6K | Sell |
40
-9
| -18% | -$1.29K | ﹤0.01% | 10100 |
|
|
2019
Q1 | $8K | Buy |
+49
| New | +$8.12K | ﹤0.01% | 8664 |
|
|
2018
Q2 | – | Sell |
-4
| Closed | -$11K | – | 10431 |
|
|
2018
Q1 | $11K | Buy |
+4
| New | +$15.2K | ﹤0.01% | 9178 |
|
|
2017
Q3 | – | Sell |
-22
| Closed | -$107K | – | 9630 |
|
|
2017
Q2 | $107K | Buy |
22
+10
| +83% | +$49.8K | ﹤0.01% | 8659 |
|
|
2017
Q1 | $68K | Sell |
12
-7
| -37% | -$48.8K | ﹤0.01% | 8517 |
|
|
2016
Q4 | $128K | Buy |
+19
| New | +$195K | ﹤0.01% | 8956 |
|
|
2016
Q2 | – | Sell |
-48
| Closed | -$987K | – | 9332 |
|
|
2016
Q1 | $987K | Buy |
48
+21
| +78% | +$316K | ﹤0.01% | 5112 |
|
|
2015
Q4 | $536K | Buy |
+27
| New | +$571K | ﹤0.01% | 6632 |
|
|
2015
Q2 | – | Sell |
-12
| Closed | -$238K | – | 10466 |
|
|
2015
Q1 | $238K | Buy |
+12
| New | +$214K | ﹤0.01% | 8374 |
|
|
2014
Q2 | – | Sell |
-16
| Closed | -$360K | – | 10119 |
|
|
2014
Q1 | $360K | Buy |
+16
| New | +$331K | ﹤0.01% | 7306 |
|
Other funds holding TOVX
IC
VF
XT
Jeff Yass's TOVX Position: Q2 2026 in Review
Jeff Yass opened a new position in Theriva Biologics (TOVX) in Q2 2026: 24,064 shares worth $6.02K. The stake represents ﹤0.01% of the portfolio and ranks #13177 among its holdings. This is a return to the name: Jeff Yass previously reported a position in TOVX as recently as Q4 2023.
Jeff Yass first reported a position in TOVX in Q1 2014 and has held it in 20 quarters since. The position peaked at $987K in Q1 2016. 26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.
- Jeff Yass held 24,064 shares of Theriva Biologics worth $6.02K as of Q2 2026.
- Theriva Biologics was a new Jeff Yass position in Q2 2026.
- Theriva Biologics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #13177 holding.
- Jeff Yass first reported a position in Theriva Biologics in Q1 2014 and has held it in 20 quarters since.
- Jeff Yass's Theriva Biologics position peaked at $987K in Q1 2016.
- 26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.